Are We Poised for a Buying Spree?
With Current High Company Valuations M&As are Scarce
By Peter Winter
Monday, July 22, 2013
Mergers and acquisitions have always been a regular staple in the biotech industry . . . until this year that is. Can it be possible that there won't be at least one blockbuster deal executed by the end of December?
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.